Item 8.01 Other Events.
On January 19, 2021, Taysha Gene Therapies, Inc. (the "Company") issued a press
release entitled "Taysha Gene Therapies Receives Rare Pediatric Disease
Designation and Orphan Drug Designations for TSHA-105 for the Treatment of
Epilepsy Caused by SLC13A5 Deficiency." The full text of the press release is
attached as Exhibit 99.1 to this Current Report on Form 8-K.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit
No. Description
99.1 Press release, dated January 19, 2021.
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses